ArriVent Biopharma Funding & Investors

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

Total Amount Raised: $305,000,000

ArriVent Biopharma Funding Rounds

IPO
Unknown
Jan 1, 2024
Series B
$155,000,000
Dec 28, 2022
Series B Investors
General Catalyst
Sofinnova
Octagon Capital Advisors
Unicorn Capital Partners
Infinitum Asset Management
OrbiMed Advisors
Terra Magnum Capital Partners (""""TMCP"""")""
HBM Healthcare Investments
Sequoia China
Boyu Capital
AIHC Capital
Catalio Capital Management
Lilly Asia Ventures
Shanghai Healthcare Capital
Sirona Capital Pty
Infinitum Partners
HBM Partners
Series A
$69,000,000
Feb 14, 2022
Series A Investors
Lyra Capital
Octagon Capital Advisors
Hillhouse Investment
OrbiMed Advisors
Lilly Asia Ventures
Boyu Capital
Series A
$81,000,000
Jun 29, 2021
Series A Investors
Hillhouse Investment
Lyra Capital
OrbiMed Advisors
Octagon Capital Advisors
Lilly Asia Ventures
Boyu Capital

Funding info provided by Diffbot.